Exenatide vs GLP-1

Native GLP-1 is degraded by the enzyme DPP-4 within minutes, which is why it is impractical as a drug. Exenatide (exendin-4) activates the same receptor but resists DPP-4.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Exenatide

A synthetic version of exendin-4, a 39-amino-acid peptide from Gila monster venom and the first GLP-1 receptor agonist approved as a medicine.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

🧪

GLP-1

The native 30-amino-acid incretin hormone from intestinal L-cells that every GLP-1 receptor agonist imitates.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

SIDE BY SIDE

	Exenatide	GLP-1
The key difference	DPP-4-resistant exendin-4	Native hormone, broken down in minutes
Class	Incretin & metabolic	Incretin & metabolic
Mechanism	Exendin-4 shares about 53% homology with GLP-1 but resists DPP-4 degradation.	GLP-1 is cut from proglucagon in gut L-cells and some brainstem neurons.
Status	Approved for type 2 diabetes (twice-daily and weekly forms); extensively used in preclinical research including neuro and β-cell studies.	Endogenous hormone and research reference; long-acting analogues (semaglutide, liraglutide, dulaglutide, tirzepatide) are approved medicines.
Reported safety signals	Nausea is the characteristic early effect; reviews cover pharmacokinetics, adverse effects and interactions.	Native GLP-1 is too short-lived for therapeutic use; class effects of its analogues are gastrointestinal first.
A key study	Reviews exenatide’s pharmacology, pharmacokinetics, efficacy and adverse effects; derived from Gila monster saliva. (Am J Health Syst Pharm 2006, PMID 16484515)	A foundational review of GLP-1 production from proglucagon and its physiological actions. (Physiol Rev 2007, PMID 17928588)

WHEN TO RESEARCH WHICH

Native GLP-1 for physiology; exenatide for the first practical receptor agonist. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Exenatide] Exenatide — Am J Health Syst Pharm 2006. PMID 16484515
[Exenatide] Exenatide. Amylin/Eli Lilly — Curr Opin Investig Drugs 2003. PMID 12808888
[Exenatide] Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system — Sci Transl Med 2024. PMID 38985854
[GLP-1] The physiology of glucagon-like peptide 1 — Physiol Rev 2007. PMID 17928588
[GLP-1] Glucagon-like peptide 1 (GLP-1) — Mol Metab 2019. PMID 31767182
[GLP-1] Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics — Br J Pharmacol 2022. PMID 34519026

FREQUENTLY ASKED

What is the difference between Exenatide and GLP-1?

Native GLP-1 is degraded by the enzyme DPP-4 within minutes, which is why it is impractical as a drug. Exenatide (exendin-4) activates the same receptor but resists DPP-4.

What is the regulatory status of Exenatide and GLP-1?

Exenatide: Approved for type 2 diabetes (twice-daily and weekly forms); extensively used in preclinical research including neuro and β-cell studies. GLP-1: Endogenous hormone and research reference; long-acting analogues (semaglutide, liraglutide, dulaglutide, tirzepatide) are approved medicines.

What safety signals have been reported?

Exenatide: Nausea is the characteristic early effect; reviews cover pharmacokinetics, adverse effects and interactions. GLP-1: Native GLP-1 is too short-lived for therapeutic use; class effects of its analogues are gastrointestinal first.

Which studies is this comparison based on?

For Exenatide: “Exenatide” (PMID 16484515); “Exenatide. Amylin/Eli Lilly” (PMID 12808888); “Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system” (PMID 38985854). For GLP-1: “The physiology of glucagon-like peptide 1” (PMID 17928588); “Glucagon-like peptide 1 (GLP-1)” (PMID 31767182); “Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics” (PMID 34519026).